Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients-Reference-Cited by-同舟云学术

Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients

Published:2005-11-01 Issue:31 Volume:23 Page:8136-8139
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Willett Christopher G.¹,Boucher Yves²,Duda Dan G.²,di Tomaso Emmanuelle²,Munn Lance L.²,Tong Ricky T.²,Kozin Sergey V.²,Petit Lucine²,Jain Rakesh K.²,Chung Daniel C.³,Sahani Dushyant V.⁴,Kalva Sanjeeva P.⁴,Cohen Kenneth S.⁵,Scadden David T.⁵,Fischman Alan J.⁶,Clark Jeffrey W.⁷,Ryan David P.⁷,Zhu Andrew X.⁷,Blaszkowsky Lawrence S.⁷,Shellito Paul C.⁸,Mino-Kenudson Mari⁹,Lauwers Gregory Y.⁹

Affiliation:

1. Department of Radiation Oncology, Duke University Medical Center, Durham, NC

2. Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

3. Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA

4. Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

5. Center for Regenerative Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, and Harvard Stem Cell Institute, Harvard University, Cambridge, MA

6. Department of Nuclear Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA

7. Division of Hematology/Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

8. Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA

9. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2005.02.5635

Reference16 articles.

1. Ellis LM, Kirkpatrick P: Bevacizumab. Nat Rev Drug Discov 4:S8,2005–S9,

2. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

3. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

4. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

5. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors

Cited by 381 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Nintedanib and Anti-Angiogenic Agents on Uveal Melanoma Cell Behavior;Investigative Opthalmology & Visual Science;2024-02-21

2. PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma;Cancer Immunology, Immunotherapy;2024-01

3. Pathological angiogenesis: mechanisms and therapeutic strategies;Angiogenesis;2023-04-15

4. Vitreous protein networks around ANG2 and VEGF in proliferative diabetic retinopathy and the differential effects of aflibercept versus bevacizumab pre-treatment;Scientific Reports;2022-12-06

5. Tumor Angiogenesis;Holland‐Frei Cancer Medicine;2022-10-21